Format

Send to

Choose Destination
Cell Mol Life Sci. 2017 Nov;74(22):4121-4132. doi: 10.1007/s00018-017-2573-2. Epub 2017 Jun 16.

Telomerase and drug resistance in cancer.

Author information

1
Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Poznan, Poland.
2
Centre for Orthodontic Mini-implants at the Department and Clinic of Maxillofacial Orthopedics and Orthodontics, Poznan University of Medical Sciences, Poznan, Poland.
3
Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Poznan, Poland. blazejr@ump.edu.pl.

Abstract

It is well known that a decreased expression or inhibited activity of telomerase in cancer cells is accompanied by an increased sensitivity to some drugs (e.g., doxorubicin, cisplatin, or 5-fluorouracil). However, the mechanism of the resistance resulting from telomerase alteration remains elusive. There are theories claiming that it might be associated with telomere shortening, genome instability, hTERT translocation, mitochondria functioning modulation, or even alterations in ABC family gene expression. However, association of those mechanisms, i.e., drug resistance and telomerase alterations, is not fully understood yet. We review the current theories on the aspect of the role of telomerase in cancer cells resistance to therapy. We believe that revealing/unravelling this correlation might significantly contribute to an increased efficiency of cancer cells elimination, especially the most difficult ones, i.e., drug resistant.

KEYWORDS:

Cancer; Drug resistance; G-quadruplex stabilizers; Telomerase; Telomere shortening; Telomeres; hTERT expression

PMID:
28623509
PMCID:
PMC5641272
DOI:
10.1007/s00018-017-2573-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center